Importantly, we identified and analyzed the key regulatory roles of several indicators, particularly LRP1B and APC. LRP1B mutations were frequently accompanied by higher TMB scores in both non-small cell lung cancer and pan-cancer cohorts and led to better immune benefits, thereby suggesting that LRP1B mutation stratification may play a guiding role in immunotherapy. Here, APC is linked to non-small cell lung carcinoma.